Companies › Azafaros
1 active drug program in 4 registered trials: 3 Phase 3, 1 Phase 2; Metabolic and endocrine; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nizubaglustat (AZ-3102) Glucosidase inhibitor | GBA, UGCG | Phase 3 | Gangliosidoses, GM2; Niemann-Pick Type C Disease; GM2 Gangliosidosis | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07399704 | Nizubaglustat (AZ-3102) | Phase 2 | GM2 Gangliosidosis | Metabolic and endocrine | Jun 2027 |
| NCT07082543 | Nizubaglustat (AZ-3102) | Phase 3 | Gangliosidoses, GM2 | Metabolic and endocrine | Feb 2028 |
| NCT07054515 | Nizubaglustat (AZ-3102) | Phase 3 | Niemann-Pick Type C Disease | Metabolic and endocrine | May 2028 |
| NCT07082725 | Nizubaglustat (AZ-3102) | Phase 3 | Niemann-Pick Type C Disease | Metabolic and endocrine | May 2028 |
Lingyi Biotech Spur Therapeutics Prevail Therapeutics Bial R&D Investments Amicus Therapeutics Sanofi Idorsia Pharmaceuticals
Fresenius Kabi Renibus Therapeutics Chendu DIAO Pharmaceutical Group Kowa Company Waterstone Pharmaceutical (Wuhan)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.